Tencent Hunyuan announced on November 5 that since Hunyuan Hy4 was first integrated into WorkBuddy on November 4, 2026, its significantly enhanced Agent capabilities have drawn enthusiastic feedback from users and developers, with many users hitting their quota limits in WorkBuddy's task queue on the very first day. To safeguard user experience, the Hy4 inference cluster has been urgently expanded tenfold and free trial quotas for users have been raised, with resources to be dynamically allocated on an ongoing basis.

Market Outlook

US stocks closed sharply lower overnight, with the Dow Jones Industrial Average falling 1,833.06 points, or 3.44%, to 51,523.06; the S&P 500 dropping 334.89 points, or 4.36%, to 7,353.73; and the Nasdaq Composite plunging 1,421.51 points, or 5.52%, to 24,315.0. Major tech stocks fell broadly, with Apple down 1.53%, Amazon down 2.19%, Google-A down 2.20%, Microsoft down 3.58%, and Meta down 3.96%. The AI supply chain was hit hard, with the Philadelphia Semiconductor Index dropping more than 12%; Nvidia, Qualcomm, and ASML each fell over 9%, Intel dropped more than 10%, and AMD plunged over 17%. Memory chip stocks led the decline, with SanDisk down 22.26%, Micron Technology down 17.46%, Western Digital down 17.35%, and Seagate Technology down 16.25%, as the market worries that a Democrat-led Congress will tighten data center approval restrictions, suppressing memory demand and product pricing. Optical communications stocks also tumbled, with Applied Optoelectronics down 20.89%, Lumentum down 18.68%, Ciena down 15.22%, Fabrinet down 14.25%, and Corning down 12.92%, as opposition to data center expansion in key construction hubs such as Texas and Georgia could delay AI capital expenditure. Elon Musk's massive political spending sparked market concerns, sending Tesla and SpaceX sharply lower, with Tesla down 10.77% and SpaceX down 9.05%. Popular Chinese concept stocks bucked the trend, with the Nasdaq Golden Dragon China Index up 0.43%. NetEase rose 4.37%, JD.com gained 3.28%, Alibaba added 2.64%, and Bilibili advanced 2.67%. The Hang Seng Index ADR declined, closing at 24,368.50 on a proportional basis, down 428.48 points, or 1.73%, from the Hong Kong close. On the New York Mercantile Exchange, the front-month WTI crude oil futures contract rose $2.47 to $90.59 per barrel, up 2.80%. COMEX front-month gold futures rose $20.40, or 0.50%, to $4,093.4 per ounce.

Key Developments to Watch

US Democrats are pushing for a super AI ban that would impose 20-year prison sentences for individual violations and forced dissolution for companies, with penalties comparable to those for illegally developing nuclear weapons. According to overseas reports, US Representative Yassamin Ansari (Arizona) wrote on a social network platform on November 4 local time: "Democrats need to put a pause on advanced artificial intelligence development at the top of the agenda on day one, regulate runaway industries, and ban artificial superintelligence." The post was published less than 24 hours after Democrats regained control of both the House and Senate in the midterm elections. Notably, Ansari's call to "ban artificial superintelligence" is not an impromptu proposal. The Senate version S.5493 was introduced by Bernie Sanders on September 23, and the House version H.R.10538 was introduced by Casar on September 24, both currently in "Introduced" status and not yet through committee review.

Huaqin Technology (03296) plans to invest 1 billion yuan in Jingyi Integrated. Huaqin Technology announced that its wholly-owned subsidiary plans to join hands with Jinghe Integrated and Hefei Construction Investment to jointly increase capital in Jingyi Integrated, a wholly-owned subsidiary of Jinghe Integrated, at a price of 1.00 yuan per registered capital unit, with total monetary capital injection of 9.1 billion yuan. Of this, the company's wholly-owned subsidiary plans to contribute 1 billion yuan. Before the capital increase, Hefei Qinhe did not hold any equity in Jingyi Integrated; after completion, Hefei Qinhe will hold 9.01% equity in Jingyi Integrated.

Jinghe Integrated (02249) plans to join Hefei Construction Investment and Hefei Qinhe in injecting 9.1 billion yuan into Jingyi Integrated. Jinghe Integrated announced that it plans to join Hefei Construction Investment and Hefei Qinhe to jointly increase capital in its wholly-owned subsidiary Jingyi Integrated at a price of 1 yuan per registered capital unit, with total capital injection of 9.1 billion yuan. Of this, the company will contribute 5.1 billion yuan, Hefei Construction Investment 3 billion yuan, and Hefei Qinhe 1 billion yuan. After the capital increase, Jingyi Integrated's registered capital will rise from 2 billion yuan to 11.1 billion yuan, and the company's shareholding will decrease from 100% to 63.96%, remaining a controlling subsidiary. Jingyi Integrated is the construction entity for Jinghe Integrated's Phase IV project, with a total investment of 35.5 billion yuan, currently building a 12-inch wafer manufacturing line with a capacity of approximately 55,000 wafers per month, focusing on 40nm and 28nm CIS, OLED, and logic processes, with products widely applicable to OLED display panels, AI phones, AI computers, smart cars, and artificial intelligence.

Qyuns Therapeutics-B (02509) entered into an exclusive licensing agreement with CALDERA THERAPEUTICS for a preclinical bispecific antibody program targeting TL1A and IL-17. Under the terms and conditions of the licensing agreement, Caldera Therapeutics was granted exclusive, royalty-bearing, transferable, and sublicensable rights to research, develop, register, manufacture, and commercialize candidate products derived from the licensed program worldwide. In return, the company or its designated subsidiaries will be entitled to receive a one-time, non-refundable, non-creditable upfront payment of $30 million. Subject to achieving certain clinical development, regulatory, and commercial milestones, the group may also receive additional payments of up to $750 million. During a specified period after the first commercial sale of products derived from the licensed program, the group will also be entitled to receive tiered royalties on net sales.

Hua Hong Semiconductor (01347) reported third-quarter profit attributable to shareholders of $123.4 million, up 147.1% year-on-year, with sales revenue reaching a new historical high. Profit attributable to owners of the parent company was $123.4 million, up 147.1% year-on-year and 77.7% quarter-on-quarter. Basic earnings per share were $0.066. The announcement stated that in the past quarter, Hua Hong Semiconductor achieved sales revenue of $987.1 million, up 19.9% year-on-year on a restated comparable basis (excluding Huali Microelectronics, sales revenue was $803.4 million, above the upper end of the previous quarter's guidance range of $770 million to $780 million). Gross margin was 24.6%, up 7.6 percentage points year-on-year (excluding Huali Microelectronics, gross margin was 19.9%, above the upper end of the previous quarter's guidance range of 16% to 18%).

GUSHENGTANG (02273) plans to acquire controlling stakes in Nanjing Shijinmo, Nanjing Baihui, Gulou Yirun, and Chengdu Qingyang to expand its offline medical institution network. After these acquisitions are completed, Nanjing Shijinmo, Nanjing Baihui, Gulou Yirun, and Chengdu Qingyang (collectively the "target companies") will become subsidiaries of the company, and their financial results will be consolidated into the group's consolidated financial statements.

IMAX CHINA (01970): IMAX Corporation reported net profit attributable to shareholders of $133 million for the first three quarters, up 289.71% year-on-year. IMAX CHINA announced the results of its controlling shareholder IMAX Corporation for the nine months ended September 30, 2026, with revenue of $359 million, up 25.88% year-on-year; net profit attributable to common shareholders of $133 million, up 289.71% year-on-year; and net profit per share of $2.44.

FIT HON TENG (06088) reported net profit from continuing operations of $88.231 million for the first three quarters, down 15.46% year-on-year. FIT HON TENG announced that for the nine months ended September 30, 2026, the group achieved revenue and other operating income of $3.873 billion, up 6.72% year-on-year; net profit from continuing operations was $88.231 million, down 15.46% year-on-year.

Wynn Macau (01128) controlling shareholder Wynn Resorts, Limited reported third-quarter Macau operating revenue of approximately $108 million, down 39.15% year-on-year. Wynn Macau announced the third-quarter 2026 results of its controlling shareholder Wynn Resorts, Limited, with Macau operating revenue of approximately $108 million, down 39.15% year-on-year. Adjusted property EBITDAR was approximately $255 million, down 17.19% year-on-year.

Stock in Focus

BEONE MEDICINES (06160) reported adjusted net profit of approximately $1.358 billion for the first three quarters, up 96% year-on-year, and raised its full-year guidance. BeiGene announced its third-quarter 2026 results, with total revenue of approximately $1.89 billion, up 34% year-on-year; net product revenue of approximately $1.855 billion, up 33% year-on-year. Net profit was approximately $385 million, up 208% year-on-year; adjusted net profit was approximately $539 million, up 77% year-on-year. Free cash flow was $474 million, an increase of $119 million from the same period last year. For the first three quarters of 2026, total revenue was approximately $5.108 billion, up 33% year-on-year; net profit was $849 million, up 285% year-on-year; adjusted net profit was approximately $1.358 billion, up 96% year-on-year. In the third quarter of 2026, GAAP gross margin (gross profit as a percentage of global product revenue) was 88%, compared to 86% in the same period last year. The year-on-year increase in gross margin was mainly driven by the increased proportion of BRUKINSA® global sales revenue in the company's product portfolio. Meanwhile, production costs for BRUKINSA® and TEVIMBRA® declined due to improved production efficiency, but this positive impact was offset by a $22 million non-cash intangible asset impairment loss related to the company's decision to discontinue promotion of POBEICIZUMAB®. On an adjusted basis (excluding depreciation and amortization, and excluding the aforementioned impairment loss), product sales gross margin increased from 86% in the same period last year to 90%.